Physician profile
Eric Gancedo
NPI 1588037253
$635.08
in general payments reported to CMS, 2019-2025
11 companies · $18.64 in 2025
The $18.64 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $185 · 2022: $79.33 · 2023: $128 · 2024: $224 · 2025: $18.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $370.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $206.10 | 2021-2024 | Otezla, Repatha |
| Lilly USA, LLC | $129.19 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Novartis Pharmaceuticals Corporation | $100.19 | 2022-2024 | |
| Glaxosmithkline, LLC. | $67.53 | 2023-2024 | Trelegy Ellipta |
| Abbvie INC. | $24.21 | 2021 | |
| Dexcom, INC. | $23.93 | 2024 | Dexcom G6 Transmitter |
| Alfasigma USA, INC. | $23.24 | 2021 | |
| Gilead Sciences, INC. | $16.48 | 2021 | |
| Nabriva Therapeutics, Plc | $16.41 | 2022 | |
| Amarin Pharma, INC. | $14.07 | 2021 | |
| Astellas Pharma US INC | $13.73 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Gancedo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.